Vanda Pharmaceuticals Inc. Stock News

Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Conference Call and Webcast to Follow WASHINGTON , Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on

From the commercialization front, Vanda Pharmaceuticals is taking prudent steps to boost Hetlioz and Fanapt sales. The company recently planted long-term growth via the OliPas partnership for ASO deve

Vanda Pharmaceuticals is a stellar growth stock trading near its cash position. Despite the latest revenue trend aberration, Vanda is still set to post significant sales increase for Fiscal 2022.

WASHINGTON , Sept. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C.

The latest meme-stock craze was "doomed to wane" partially because investor sentiment is still predominantly bearish, said Vanda Research.

Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos - President & Chief Executive Officer Kevin Moran - S

Conference Call and Webcast to Follow WASHINGTON , July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 o

WASHINGTON , June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New

I am quite impressed with Vanda Pharmaceuticals' investing thesis. Though it cooled off recently, Vanda is still positing significant revenues that I expect would leap to a higher level either next ye

Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos – President & Chief Executive Officer Kevin Moran –

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The�

Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on